Prelude therapeutics reports full year 2023 financial results and outlines key objectives for 2024

First-in-class iv smarca2 degrader and potentially best-in-class cdk9 inhibitor on track to generate potential proof-of-concept data in 2024

PRLD Ratings Summary

PRLD Quant Ranking